< Zurück < Zurück
von 6
Weiter > Weiter >
Top-News
< Zurück < Zurück
von 6
Weiter > Weiter >
  • Startseite
  • Aktien
  • Immunic Aktie
  • News

    • Immunic News

    1,46 $ +8,15% +0,11 $
    In : 1,3897 € | 22:00:00 Uhr Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2PHD4
    ISIN: US4525EP1011
    US-Symbol: IMUX
    Typ: Aktie

    Immunic News

    < Zurück < Zurück
    von 6
    Weiter > Weiter >
    06.09.23 - PR Newswire
    Immunic to Participate in Industry and Investor Conferences in September
    Immunic to Participate in Industry and Investor Conferences in September PR Newswire
    17.08.23 - 4investors
    Immunic: Wichtiger Meilenstein
    17.08.23 - PR Newswire
    Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
    Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis PR Newswire
    03.08.23 - 4investors
    Immunic: Steigende F&E-Investitionen treiben Quartals-Verlust
    03.08.23 - PR Newswire
    Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
    Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire
    01.08.23 - PR Newswire
    Immunic to Participate in Investor and Scientific Conferences in August
    Immunic to Participate in Investor and Scientific Conferences in August PR Newswire
    27.07.23 - PR Newswire
    Thinking about buying stock in Joby Aviation, Aurora Innovation, Terawulf, Ardelyx, or Immunic?
    Thinking about buying stock in Joby Aviation, Aurora Innovation, Terawulf, Ardelyx, or Immunic? PR Newswire
    27.07.23 - PR Newswire
    Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
    Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update PR Newswire
    29.06.23 - PR Newswire
    Immunic to Participate in Scientific and Investor Conferences in July
    Immunic to Participate in Scientific and Investor Conferences in July PR Newswire
    30.05.23 - PR Newswire
    Immunic to Participate in Scientific and Investor Conferences in June
    Immunic to Participate in Scientific and Investor Conferences in June PR Newswire
    17.05.23 - PR Newswire
    Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
    Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis PR Newswire
    11.05.23 - 4investors
    Immunic meldet Quartals­zahlen - klinische Studie mit IMU-856 in Vorbereitung
    11.05.23 - PR Newswire
    Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
    Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire
    09.05.23 - PR Newswire
    Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update
    Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update PR Newswire
    06.05.23 - PR Newswire
    Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
    Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action PR Newswire
    04.05.23 - PR Newswire
    Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
    Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-​of-Concept for New Therapeutic Approach to Gastrointestinal ...
    27.04.23 - PR Newswire
    Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
    Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. PR Newswire
    26.04.23 - PR Newswire
    Immunic to Participate in Investor and Scientific Conferences in May
    Immunic to Participate in Investor and Scientific Conferences in May PR Newswire
    05.04.23 - PR Newswire
    Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
    Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-​to-Severe Ulcerative Colitis PR Newswire
    16.03.23 - PR Newswire
    Thinking about buying stock in Thermogenesis, UiPath, Snap, Immunic, or Enovix?
    Thinking about buying stock in Thermogenesis, UiPath, Snap, Immunic, or Enovix? PR Newswire
    < Zurück < Zurück
    von 6
    Weiter > Weiter >

    Newssuche

    Videos

    09:00 Uhr
    Technical Trading: Kaffee Long Chance
    Coffee Long Typ: Turbo Open End WKN: VP4Z37 Hebel: 2,97 Laufzeit: OpenEnd Einstieg: Market ... Mehr »